Bicara Therapeutics Inc (BCAX) Stock Price, Quote & News

Company Profile

Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the development of bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines a clinically validated epidermal growth factor receptor directed monoclonal antibody bound to human transforming growth factor beta for the treatment of solid tumors. The company was incorporated in 2018 and is based in Boston, Massachusetts.

Industry: Biotechnology

Sector: Healthcare

Phone: 617 468 4219

Website: www.bicara.com

Address:

116 Huntington Avenue, Suite 703, Boston, United States

ajmrtxl Jul. 2 at 4:43 PM

$BCAX 's latest data on SqueezeFinder

0 · Reply

justiceforb_85 Jun. 18 at 5:00 PM

$BCAX look forward to data later this year for ficerafusp in CRC.

1 · Reply

Doozio Jun. 17 at 9:13 PM

$BCAX huckleberries n $$$ patterns ONTO 🐒🍌🧠⏰♾️

0 · Reply

LewisDaKat Jun. 13 at 10:30 AM

$BCAX What Does the Bicara Therapeutics CEO's Sale of 15,000 Shares Mean for Investors? https://marketwirenews.com/stock/bcax/news/what-does-the-bicara-therapeutics-ceo-s-sale-of-15-0-8301590123242962.html?utm_source=stocktwits

0 · Reply

MarketBeat May. 22 at 3:10 PM

https://marketbeat.com/a/8669441/ $BCAX Bicara Therapeutics ASCO Data Bolster Ficerafusp Alfa in Head and Neck Cancer

0 · Reply

MarketBeat May. 14 at 9:10 PM

https://marketbeat.com/a/8654998/ $BCAX Bicara Therapeutics Touts Cancer Drug Progress Ahead of 2026 Pivotal Data

0 · Reply

SuperGreenToday May. 13 at 1:39 AM

$BCAX Share Price: $22.38 Contract Selected: Aug 21, 2026 $17.5 Calls Buy Zone: $3.15 – $3.89 Target Zone: $5.35 – $6.54 Potential Upside: 61% ROI Time to Expiration: 100 Days | Updates via https://fxcapta.com/stockinfo/

0 · Reply

EarningsInsider May. 11 at 3:47 PM

https://www.marketbeat.com/earnings/reports/2026-5-11-bicara-therapeutics-inc-stock/ $BCAX Bicara Therapeutics Earnings Transcript

0 · Reply

notreload_ai May. 11 at 2:40 PM

$SANA $ARXS $BCAX $BBOT $WSE $URGN -- THE WSJ

0 · Reply

MarketBeat May. 11 at 2:08 PM

https://marketbeat.com/a/8648244/ $BCAX Bicara Therapeutics Q1 Earnings Call Highlights

0 · Reply

Bicara Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

May 22, 2026, 8:30 AM EDT - 6 weeks ago

Bicara Therapeutics Transcript: Study update

May 22, 2026, 8:30 AM EDT - 6 weeks ago

Bicara Therapeutics Press release: Study update

May 22, 2026, 8:30 AM EDT - 6 weeks ago

Bicara Therapeutics Slides: Study update

2026-05-21T21:00:25.000Z - 6 weeks ago

Bicara Therapeutics management to meet with Cantor

May 21, 2026, 5:00 PM EDT - 6 weeks ago

Ficerafusp Alfa Plus Pembrolizumab Demonstrated Differentiated Three-Year Overall Survival and Deep Responses Driven by TGF-β Inhibition in 1L R/M HPV-Negative HNSCC

May 13, 2026, 12:20 PM EDT - 7 weeks ago

Bicara Therapeutics Transcript: Bank of America Global Healthcare Conference 2026

May 13, 2026, 8:30 AM EDT - 7 weeks ago

Bicara Therapeutics Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4)

2026-05-12T16:11:02.000Z - 7 weeks ago

Bicara Therapeutics price target raised to $37 from $36 at Morgan Stanley

2026-05-12T11:03:50.000Z - 7 weeks ago

Bicara Therapeutics price target raised to $18 from $16 at Goldman Sachs

2026-05-11T17:03:43.000Z - 7 weeks ago

Bicara Therapeutics reports Q1 EPS (93c), consensus (65c)

May 11, 2026, 8:30 AM EDT - 7 weeks ago

Bicara Therapeutics Earnings Call Transcript: Q1 2026

May 11, 2026, 8:30 AM EDT - 7 weeks ago

Bicara Therapeutics Earnings release: Q1 2026

May 11, 2026, 8:30 AM EDT - 7 weeks ago

Bicara Therapeutics Slides: Q1 2026

May 11, 2026, 8:30 AM EDT - 7 weeks ago

Bicara Therapeutics Quarterly report: Q1 2026

May 11, 2026, 7:30 AM EDT - 7 weeks ago

Bicara Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update

2026-05-11T08:53:07.000Z - 7 weeks ago

Bicara Therapeutics initiated with a Buy at Guggenheim

2026-05-11T00:45:05.000Z - 7 weeks ago

Bicara Therapeutics initiated with a Buy at Guggenheim

May 10, 2026, 9:45 AM EDT - 7 weeks ago

Bicara Therapeutics Slides: Corporate presentation

May 4, 2026, 8:30 AM EDT - 2 months ago

Bicara Therapeutics to Report First Quarter 2026 Financial Results and Business Updates on May 11, 2026, at 8:30 AM ET

Apr 27, 2026, 8:00 AM EDT - 2 months ago

Bicara Therapeutics Proxy statement: Proxy filing

Apr 27, 2026, 8:00 AM EDT - 2 months ago

Bicara Therapeutics Proxy statement: Proxy filing

Apr 3, 2026, 8:30 AM EDT - 3 months ago

Bicara Therapeutics Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4)

2026-04-02T15:05:41.000Z - 3 months ago

Bicara Therapeutics management to meet with Citizens

2026-03-31T10:53:42.000Z - 3 months ago

Bicara Therapeutics price target raised to $16 from $11 at Wells Fargo

2026-03-31T10:24:11.000Z - 3 months ago

Bicara Therapeutics price target raised to $16 from $14 at Goldman Sachs

Mar 30, 2026, 8:30 AM EDT - 3 months ago

Bicara Therapeutics Earnings Call Transcript: Q4 2025

Mar 30, 2026, 8:30 AM EDT - 3 months ago

Bicara Therapeutics Annual report: Q4 2025

Mar 30, 2026, 8:30 AM EDT - 3 months ago

Bicara Therapeutics Earnings release: Q4 2025

Mar 30, 2026, 8:30 AM EDT - 3 months ago

Bicara Therapeutics Slides: Q4 2025

2026-03-30T11:41:21.000Z - 3 months ago

Bicara Therapeutics reports Q4 EPS (68c), consensus (65c)

Mar 30, 2026, 7:30 AM EDT - 3 months ago

Bicara Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Mar 27, 2026, 8:00 AM EDT - 3 months ago

Bicara Therapeutics Slides: Corporate presentation

2026-03-25T10:25:43.000Z - 3 months ago

BofA starts Bicara Therapeutics with a Buy on head and neck cancer potential

2026-03-25T10:10:52.000Z - 3 months ago

Bicara Therapeutics initiated with a Buy at BofA

Mar 23, 2026, 8:30 AM EDT - 3 months ago

Bicara Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Business Updates on March 30, 2026, at 8:30 AM ET

Mar 10, 2026, 11:30 AM EDT - 4 months ago

Bicara Therapeutics Transcript: Barclays 28th Annual Global Healthcare Conference

2026-03-04T13:37:32.000Z - 4 months ago

Bicara Therapeutics announces inducement grants

Mar 2, 2026, 1:10 PM EST - 4 months ago

Bicara Therapeutics Transcript: TD Cowen 46th Annual Health Care Conference

Feb 26, 2026, 4:01 PM EST - 4 months ago

Bicara Therapeutics Announces Closing of Oversubscribed Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares

2026-02-25T11:00:14.000Z - 4 months ago

Bicara Therapeutics 7.175M share Spot Secondary priced at $16.00

Feb 24, 2026, 11:13 PM EST - 4 months ago

Bicara Therapeutics Announces Pricing of $150 Million Public Offering of Common Stock and Pre-Funded Warrants

2026-02-24T21:35:27.000Z - 4 months ago

Bicara Therapeutics announces proposed offering of $150M in common stock

Feb 24, 2026, 4:01 PM EST - 4 months ago

Bicara Therapeutics Announces Proposed Public Offering of Common Stock

Feb 24, 2026, 7:00 AM EST - 4 months ago

Bicara Therapeutics Slides: Corporate presentation

Feb 23, 2026, 8:30 AM EST - 4 months ago

Bicara Therapeutics to Participate in Upcoming Investor Conferences

Feb 20, 2026, 8:30 AM EST - 4 months ago

Bicara Therapeutics Transcript: Study update

Feb 20, 2026, 8:30 AM EST - 4 months ago

Bicara Therapeutics Press release: Study update

Feb 20, 2026, 8:30 AM EST - 4 months ago

Bicara Therapeutics Slides: Study update

Feb 19, 2026, 4:30 PM EST - 4 months ago

Ficerafusp Alfa 2000mg Q2W Demonstrates Deep, Durable Responses in 1L R/M HPV-Negative HNSCC and Supports Development of Less Frequent Dosing Regimen

2026-02-11T21:45:37.000Z - 5 months ago

Bicara moved to Neutral from Early-Stage Biotech at Goldman Sachs

2026-02-05T13:41:35.000Z - 5 months ago

Bicara Therapeutics announces inducement grants

Feb 5, 2026, 8:30 AM EST - 5 months ago

Bicara Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

2026-01-29T09:45:12.000Z - 5 months ago

Bicara Therapeutics initiated with an Outperform at Citizens

Jan 12, 2026, 2:15 PM EST - 6 months ago

Bicara Therapeutics Transcript: 44th Annual J.P. Morgan Healthcare Conference

2026-01-12T13:25:47.000Z - 6 months ago

Bicara Therapeutics announces Phase 3 optimal dose of ficerafusp alfa

Jan 12, 2026, 8:00 AM EST - 6 months ago

Bicara Therapeutics Announces Phase 3 Optimal Dose and Provides 2026 Corporate Outlook

Jan 11, 2026, 7:00 AM EST - 6 months ago

Bicara Therapeutics Slides: Corporate presentation

Dec 15, 2025, 8:00 AM EST - 7 months ago

Bicara Therapeutics to Present at the J.P. Morgan 2026 Annual Healthcare Conference on Monday, January 12

Dec 6, 2025, 9:00 AM EST - 7 months ago

Bicara Therapeutics Transcript: Status Update

Dec 6, 2025, 9:00 AM EST - 7 months ago

Bicara Therapeutics Press release: Status Update

Dec 6, 2025, 9:00 AM EST - 7 months ago

Bicara Therapeutics Slides: Status Update

Dec 6, 2025, 8:00 AM EST - 7 months ago

Bicara Therapeutics' Preliminary Phase 1b Expansion Cohort Data Evaluating 750mg of Ficerafusp Alfa Weekly Plus Pembrolizumab Advances Pivotal Study Dose Selection on Track for First Quarter 2026

Dec 2, 2025, 4:30 PM EST - 7 months ago

Bicara Therapeutics Transcript: Piper Sandler 37th Annual Healthcare Conference

Dec 1, 2025, 7:00 AM EST - 7 months ago

Bicara Therapeutics Announces Publication of an Abstract with Preliminary Phase 1b Expansion Cohort Data Evaluating 750mg of Ficerafusp Alfa Weekly Plus Pembrolizumab in 1L HPV-negative R/M HNSCC at ESMO Asia 2025

Nov 10, 2025, 7:30 AM EST - 8 months ago

Bicara Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update

Nov 10, 2025, 7:30 AM EST - 8 months ago

Bicara Therapeutics Quarterly report: Q3 2025

Nov 10, 2025, 7:30 AM EST - 8 months ago

Bicara Therapeutics Earnings release: Q3 2025

Oct 13, 2025, 7:30 AM EDT - 9 months ago

Bicara Therapeutics Announces Ficerafusp Alfa Granted Breakthrough Therapy Designation by U.S. FDA for 1L HPV-Negative R/M HNSCC

Oct 3, 2025, 8:00 AM EDT - 9 months ago

Bicara Therapeutics Registration statement: Registration Filing

Sep 8, 2025, 4:05 PM EDT - 10 months ago

Bicara Therapeutics Transcript: Morgan Stanley 23rd Annual Global Healthcare Conference

Sep 3, 2025, 2:15 PM EDT - 10 months ago

Bicara Therapeutics Transcript: Wells Fargo 20th Annual Healthcare Conference 2025

Sep 3, 2025, 10:55 AM EDT - 10 months ago

Bicara Therapeutics Transcript: Cantor Global Healthcare Conference 2025

Aug 12, 2025, 8:00 AM EDT - 11 months ago

Bicara Therapeutics Quarterly report: Q2 2025

Aug 12, 2025, 8:00 AM EDT - 11 months ago

Bicara Therapeutics Earnings release: Q2 2025

Aug 12, 2025, 8:00 AM EDT - 11 months ago

Bicara Therapeutics Slides: Corporate Presentation

Aug 12, 2025, 7:30 AM EDT - 11 months ago

Bicara Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update

Jun 10, 2025, 3:20 PM EDT - 1 year ago

Bicara Therapeutics Transcript: Goldman Sachs 46th Annual Global Healthcare Conference 2025

Jun 3, 2025, 4:01 PM EDT - 1 year ago

Bicara Therapeutics to Present at the Goldman Sachs 46th Annual Global Healthcare Conference

Jun 1, 2025, 4:00 PM EDT - 1 year ago

Bicara Therapeutics Transcript: Status Update

Jun 1, 2025, 1:12 PM EDT - 1 year ago

Bicara Therapeutics Demonstrates Deep and Durable Responses with Ficerafusp Alfa Plus Pembrolizumab in 1L HPV-Negative R/M HNSCC at ASCO 2025

May 22, 2025, 5:00 PM EDT - 1 year ago

Bicara Therapeutics Announces Publication of an Abstract with Updated Interim Data from Phase 1/1b Trial of Ficerafusp alfa in 1L R/M HNSCC at the 2025 ASCO Annual Meeting

May 13, 2025, 7:30 AM EDT - 1 year ago

Bicara Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

May 13, 2025, 7:30 AM EDT - 1 year ago

Bicara Therapeutics Quarterly report: Q1 2025

May 13, 2025, 7:30 AM EDT - 1 year ago

Bicara Therapeutics Earnings release: Q1 2025

Apr 28, 2025, 4:01 PM EDT - 1 year ago

Bicara Therapeutics Highlights Broad Potential of Ficerafusp Alfa at AACR Annual Meeting 2025

Apr 25, 2025, 8:00 AM EDT - 1 year ago

Bicara Therapeutics Proxy statement: Proxy Filing

Apr 25, 2025, 8:00 AM EDT - 1 year ago

Bicara Therapeutics Proxy statement: Proxy Filing

Apr 23, 2025, 10:00 AM EDT - 1 year ago

Bicara Therapeutics to Present Updated Data from Ongoing Phase 1/1b Trial of Ficerafusp alfa in 1L R/M HNSCC at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting

Mar 27, 2025, 7:30 AM EDT - 1 year ago

Bicara Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Mar 27, 2025, 7:30 AM EDT - 1 year ago

Bicara Therapeutics Annual report: Q4 2024

Mar 27, 2025, 7:30 AM EDT - 1 year ago

Bicara Therapeutics Earnings release: Q4 2024

Mar 25, 2025, 4:45 PM EDT - 1 year ago

Bicara Therapeutics Announces Upcoming Presentations at AACR Annual Meeting 2025

Mar 3, 2025, 3:10 PM EST - 1 year ago

Bicara Therapeutics Transcript: TD Cowen 45th Annual Healthcare Conference

Feb 24, 2025, 4:01 PM EST - 1 year ago

Bicara Therapeutics to Present at the TD Cowen 45th Annual Health Care Conference

Feb 11, 2025, 4:01 PM EST - 1 year ago

Bicara Therapeutics Announces First Patients Enrolled in FORTIFI-HN01, a Pivotal Phase 2/3 Clinical Trial of Ficerafusp Alfa in 1L Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

Jan 27, 2025, 8:00 AM EST - 1 year ago

Bicara Therapeutics Presents Phase 1/1b Dose Expansion Results with Ficerafusp Alfa in Advanced Squamous Cancer of the Anal Canal at the 2025 ASCO Gastrointestinal Cancers Symposium

Nov 19, 2024, 9:10 AM EST - 1 year ago

Bicara Therapeutics Transcript: Stifel 2024 Healthcare Conference

Nov 12, 2024, 7:30 AM EST - 1 year ago

Bicara Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update

Nov 12, 2024, 7:00 AM EST - 1 year ago

Bicara Therapeutics Quarterly report: Q3 2024

Nov 12, 2024, 7:00 AM EST - 1 year ago

Bicara Therapeutics Earnings release: Q3 2024

Nov 11, 2024, 4:01 PM EST - 1 year ago

Bicara Therapeutics to Present at the Stifel 2024 Healthcare Conference

Sep 16, 2024, 4:01 PM EDT - 1 year ago

Bicara Therapeutics Announces Closing of $362 Million Initial Public Offering, Including Full Exercise of Underwriters' Option to Purchase Additional Shares

Sep 13, 2024, 1:28 PM EDT - 1 year ago

TPG-backed Bicara Therapeutics shares surge 46% in stellar market debut

Sep 12, 2024, 9:15 PM EDT - 1 year ago

Bicara Therapeutics Announces Pricing of Upsized Initial Public Offering

Sep 11, 2024, 6:34 PM EDT - 1 year ago

Bicara Therapeutics targets $265 mln proceeds in upsized US IPO

Sep 11, 2024, 8:00 AM EDT - 1 year ago

Bicara Therapeutics Registration statement: Registration Filing

Sep 6, 2024, 8:00 AM EDT - 1 year ago

Bicara Therapeutics Registration statement: Registration Filing

Sep 6, 2024, 7:25 AM EDT - 1 year ago

Bicara Therapeutics aims for up to $828 mln valuation in U.S. IPO

ajmrtxl Jul. 2 at 4:43 PM

$BCAX 's latest data on SqueezeFinder

0 · Reply

justiceforb_85 Jun. 18 at 5:00 PM

$BCAX look forward to data later this year for ficerafusp in CRC.

1 · Reply

Doozio Jun. 17 at 9:13 PM

$BCAX huckleberries n $$$ patterns ONTO 🐒🍌🧠⏰♾️

0 · Reply

LewisDaKat Jun. 13 at 10:30 AM

0 · Reply

MarketBeat May. 22 at 3:10 PM

https://marketbeat.com/a/8669441/ $BCAX Bicara Therapeutics ASCO Data Bolster Ficerafusp Alfa in Head and Neck Cancer

0 · Reply

MarketBeat May. 14 at 9:10 PM

https://marketbeat.com/a/8654998/ $BCAX Bicara Therapeutics Touts Cancer Drug Progress Ahead of 2026 Pivotal Data

0 · Reply

SuperGreenToday May. 13 at 1:39 AM

0 · Reply

EarningsInsider May. 11 at 3:47 PM

https://www.marketbeat.com/earnings/reports/2026-5-11-bicara-therapeutics-inc-stock/ $BCAX Bicara Therapeutics Earnings Transcript

0 · Reply

notreload_ai May. 11 at 2:40 PM

$SANA $ARXS $BCAX $BBOT $WSE $URGN -- THE WSJ

0 · Reply

MarketBeat May. 11 at 2:08 PM

https://marketbeat.com/a/8648244/ $BCAX Bicara Therapeutics Q1 Earnings Call Highlights

0 · Reply

StocktwitsEarnings May. 11 at 1:19 PM

$BCAX Q1 '26 Earnings Results & Recap Bicara Therapeutics expects its existing cash, cash equivalents, and marketable securities to fund operations into the first half of 2029, supporting ongoing operating and development plans.

0 · Reply

OpenOutcrier May. 11 at 12:41 PM

$BCAX (-11.4% pre) Bicara Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update https://ooc.bz/l/101766

0 · Reply

Quantumup May. 11 at 11:18 AM

Guggenheim🏁 $BCAX Buy; $42 $GMAB - MRUS $MRK Here's what Guggenheim said in its initiation report: https://x.com/Quantumup1/status/2053796129276358965?s=20

0 · Reply

justiceforb_85 May. 10 at 4:21 AM

$BCAX impressive data for ficerafusp with pembro in recurrent HNSCC. P1 data but could see the drug being effective in other tumor types. https://ascopubs.org/doi/10.1200/JCO-25-02027

1 · Reply

John_morrris May. 5 at 6:09 PM

$BCAX Sharing - FWIW Claire will transition into my role at the right time so not planning to hang up my boots just yet!! Kiran Mazumdar Shaw @kiranshaw , founder and chairperson of @Bioconlimited , has outlined a succession plan for the biotechnology group, identifying her niece Claire Mazumdar as her successor. Read More - https://storyboard18.com/brand-makers/k iran-mazumdar-shaw-names-claire-mazumdar-as-successor-as-biocon-plans-next-phase-97141.htm https://x.com/kiranshaw/status/2051543260565479664

0 · Reply

Laynester Apr. 19 at 11:03 AM

$CRML $INFQ $ILIT $BCAX $XSD 3 week gain report. Look at these share and etf trends for future gains. Materials and Microchips are on the heater. [CRML] +69% [INFQ] +63% [ILIT] +26% (DIVIDEND 2.7%) [BCAX] +26% [XSD] +26% (DIVIDEND .02%) Set a stop. Good to all ... all around the world including our foes. We both know not what we're doing. 100%---> 🦬

0 · Reply

Laynester Apr. 15 at 11:00 AM

$SGML $BCAX These TWO shares...(in my portfolio) are showing the BEST in ALL long term indicators. They both show 'up trends' in ALL key weekly graphical areas and UP 69% and 24% respectively, the past 3 weeks. Set a stop. Good to all! Go dancing this Friday or Saturday night...have fun! 100%--->🦬

0 · Reply

STACKD0E Apr. 13 at 3:54 PM

$BCAX $CSTM $IRDM $GSAT $WDC

0 · Reply

Laynester Apr. 10 at 11:51 AM

$INFQ $BCAX $BURL $DHC $CTVA [TGT] Did some share buying / additions pre-market today. Most were add's. The new ones are [INFQ] and [TGT] (Target not listed below in the below image). Set a stop. Good blessing to all around the world and beyond (to the dudes coming back from the dark side of the moon; unreal or is it ...real..?). 100%--->🦬

0 · Reply

Laynester Apr. 8 at 11:54 PM

$SGML $SDRL $BCAX $XTL $BURL It's been a very difficult past 3 weeks trading right? Check out these 5 % high risers in the portfolio for the past 3 weeks. [SGML] +27.60% [SDRL] +11.9% [BCAX] +11.39% [XTL] +10.88% DIV +1% [BURL] +10.55% Now that things 'seem' better after today's market news. These should start flyin and I'm a buyin (or adding when I can!). Set a stop. Good to all investors all around the world. I'm tellin ya it's a tuff room! I'm tellin ya I get no respect! ALL 5 100%--->🦬

0 · Reply

Laynester Apr. 3 at 9:07 PM

$SWMR $SGML $BCAX $MUR $HCC My top 5 daily gains in the portfolio on Thursday 4/2/2026. Got a better set? Cool m'man (woman). I'm wid ya. Not bad a all I'd say no brag just trying to make a honest livin and spread the good news to all us slave bound under worldwide tyranny. SWMR 44.5% SGML 21.4% BCAX 4.7% MUR 3.8% HCC 3.2% Smash em in the future. Set a stop. Good to all honest and moral investors around the world. All 100%--->🦬

0 · Reply

Market Cap	1.91B
Revenue (ttm)	0.00
Net Income (ttm)	-137.95M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	924,100
Avg Vol	694,922
Day's Range	N/A - N/A
Shares Out	65.70M
Stochastic %K	86%
Beta	-0.81
Analysts	Strong Sell
Price Target	$31.46